We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


ICR Collaborates With AI Drug Discovery Company To Develop Treatments for Rare Childhood Cancer

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Scientists at The Institute of Cancer Research, London, are working with Healx, a biotech company specialising in artificial intelligence (AI) to discover new possible ways of treating diffuse intrinsic pontine glioma (DIPG), an essentially untreatable brain cancer in children.

Professor Chris Jones from The Institute of Cancer Research (ICR) – a world-leading figure in the study of DIPG – and his team are collaborating with Healx, which specialises in discovering and developing new treatments for rare diseases.

By combining AI and machine learning techniques with insight from its pharmacology and drug discovery researchers, Healx has been able to make predictions about which existing drugs, already used in other diseases, could be repurposed to treat DIPG.

Identifying potential new treatment

Healx has previously used this approach to identify potential new treatments for rare cancers in partnership with childhood cancer charity aPODD.

Professor Jones is now planning to research these drugs in the laboratory to work out if they could be used as treatments.

The ICR is an internationally leading research centre in the study of childhood cancers, including in DIPG.

Professor Jones and colleagues at the ICR have led previous studies that have led to new understanding of DIPG, including the discovery of a possible genetic weakness in some cases that could be targeted by drugs.

This research has led to collaborations with partners including the Structural Genomics Consortium at the University of Oxford and open science company M4K (Medicines for Kids) Pharma to discover, develop or repurpose drugs to target DIPG.

The ICR is a world-leading academic centre in working with industry. Our interactions with commercial partners are overseen by the Enterprise Unit, our technology and transfer hub.

'Determined to find new ways of treating this disease'

Professor Chris Jones, Professor of Paediatric Brain Tumour Biology at the ICR, said:

“We’re very pleased to be partnering with Healx in the development of potential new treatments for DIPG, a rare childhood cancer with an average life expectancy of just nine months. We welcome Healx to a community of researchers, partners, donors and families who are determined to find new ways of treating this devastating disease.”

Dr Neil Thompson, Chief Scientific Officer at Healx, said:

“I am excited to be collaborating with the ICR, one of the world’s leading cancer research organisations. The expertise that Professor Chris Jones and his team bring to childhood brain cancers, and DIPG in particular, is invaluable to an organisation looking to help patients with this rare disease.

“We hope that by combining this with our ground-breaking AI technology, pharmacology expertise and comprehensive rare disease knowledge graph, we can accelerate the discovery and development of new treatments for this devastating disease.”

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.